Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

The biotech sector has not seen an IPO in six months. The market has remained frozen amid broader macro pressures and the ...

Thousands of employees across the Department of Health and Human Services are set to lose their collective bargaining rights ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Vanda claims that two generics to its sleep disorder drug Hetlioz were approved despite inadequate data and is requesting ...

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Krystal Biotech's decision follows the FDA’s rejection last month of Replimune’s RP1, which works similarly to Krystal ...

The Trump administration's ever-changing tariffs and Most Favored Nation drug pricing are part of a blizzard of unclear, ...